再鼎医药将于2026年美国癌症研究协会（AACR）年会上公布三款内部开发肿瘤候选药物的最新数据 Read more about 再鼎医药将于2026年美国癌症研究协会（AACR）年会上公布三款内部开发肿瘤候选药物的最新数据
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference - SC Read more about Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference - SC
再鼎医药宣布国家药品监督管理局批准奥凯乐®（瑞普替尼）用于治疗NTRK阳性实体瘤患者 Read more about 再鼎医药宣布国家药品监督管理局批准奥凯乐®（瑞普替尼）用于治疗NTRK阳性实体瘤患者
再鼎医药宣布同类首创药物呫诺美林曲司氯铵胶囊（凯捷乐®）在中国获批用于治疗精神分裂症 Read more about 再鼎医药宣布同类首创药物呫诺美林曲司氯铵胶囊（凯捷乐®）在中国获批用于治疗精神分裂症
再鼎医药宣布治疗特应性皮炎的IL-13/IL-31R双特异性抗体ZL-1503的全球I/Ib期研究完成首例受试者给药 Read more about 再鼎医药宣布治疗特应性皮炎的IL-13/IL-31R双特异性抗体ZL-1503的全球I/Ib期研究完成首例受试者给药
Update on Amgen’s bemarituzumab Phase 1b/3 FORTITUDE-102 Study - SC Read more about Update on Amgen’s bemarituzumab Phase 1b/3 FORTITUDE-102 Study - SC
Zai Lab Announces Participation in Investor Conferences in November and December 2025 - SC Read more about Zai Lab Announces Participation in Investor Conferences in November and December 2025 - SC